ERBB2 L866M

在结直肠癌患者来源的异种移植物中，这种突变被证明是一种激活性突变，并赋予曲妥珠单抗与奈他替尼或拉帕替尼联合使用的敏感性。
This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.